Jennison Associates’s Protagonist Therapeutics PTGX Stock Holding History

Jennison Associates’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$141M	Buy	1,151,681 +79,670	+7%	+$8.32M	0.08%	111
2026 Q1	$113M	Buy	1,072,011 +740,847	+224%	+$65.6M	0.08%	118
2025 Q4	$28.9M	Buy	+331,164	New	+$27.1M	0.02%	284
2025 Q2	–	Sell	-18,317	Closed	-$886K	–	625
2025 Q1	$886K	Buy	+18,317	New	+$768K	﹤0.01%	490
2023 Q2	–	Sell	-428,938	Closed	-$9.87M	–	615
2023 Q1	$9.87M	Buy	+428,938	New	+$7.2M	0.01%	392
2018 Q4	–	Sell	-349,697	Closed	-$3.6M	–	703
2018 Q3	$3.6M	Buy	+349,697	New	+$3.01M	﹤0.01%	506
2018 Q1	–	Sell	-100,000	Closed	-$2.08M	–	694
2017 Q4	$2.08M	Buy	+100,000	New	+$1.77M	﹤0.01%	528

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Jennison Associates's PTGX Position: Q2 2026 in Review

Jennison Associates increased its Protagonist Therapeutics (PTGX) stake by 7.4% in Q2 2026, buying an estimated $8.32M and bringing the position to 1,151,681 shares worth $141M. The position accounts for 0.08% of the portfolio, ranked #111.

Jennison Associates first reported a position in PTGX in Q4 2017 and has held it in 7 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Jennison Associates held 1,151,681 shares of Protagonist Therapeutics worth $141M as of Q2 2026.
Jennison Associates bought 79,670 Protagonist Therapeutics shares in Q2 2026, an estimated $8.32M.
Protagonist Therapeutics made up 0.08% of Jennison Associates's portfolio in Q2 2026, its #111 holding.
Jennison Associates first reported a position in Protagonist Therapeutics in Q4 2017 and has held it in 7 quarters since.
344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.